News

This 8-Year-Old Is Free of Cancer — for Now — After a 'Breakthrough' Treatment

This 8-Year-Old Is Free of Cancer — for Now — After a 'Breakthrough' Treatment

CAR T-cell therapy is one of the new immunotherapies that attempt to rally the body’s own defenses to fight malignancies. Unlike other cancer advances, it is being tested widely in children because of its stunning effectiveness in acute lymphoblastic leukemia (ALL), the most common pediatric cancer. Zane Esposito, a 13-year-old from Texas who was diagnosed with ALL in June 2010, received the therapy at Seattle Children’s and went into remission. Dr. Rebecca Gardner, a pediatric oncologist at Seattle Children’s, and Dr. Mike Jensen, director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, are quoted in the article.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.